Insulet Corp (PODD) 32.00 $PODD
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Insulet Appoints John Fallon, M.D. as New Lead Director
Marketwired - Tue Feb 10, 4:00PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced that Dr. John Fallon has been appointed Lead Director of Insulet's Board of Directors. Dr. Fallon has served on the Insulet Board since 2012 and replaces Daniel Levangie who is resigning from the Insulet Board in order to assume the newly-created role of President, Insulet Drug Delivery.
PODD: 32.00 (-0.07)
Insulet Further Enhances Executive Leadership Team to Drive Improved Commercial and Operational Performance
Marketwired - Tue Feb 10, 4:00PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the appointment of Daniel Levangie to the newly-created role of President, Insulet Drug Delivery, and Ms. Shacey Petrovic to the position of Chief Commercial Officer, both reporting directly to Patrick Sullivan, President and Chief Executive Officer. As President, Insulet Drug Delivery, Mr. Levangie will focus on developing new growth opportunities for use of the OmniPod technology in the administration of a range of pharmaceutical products. In her role as Chief Commercial Officer, Ms. Petrovic will oversee all of the Company's commercial operations, including sales, marketing, managed care and business development. These appointments further strengthen the Company's senior leadership capabilities.
PODD: 32.00 (-0.07)
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 32.00 (-0.07), DXCM: 62.68 (+0.74), NVO: 43.76 (+0.61), MOM.VN: 0.210 (+0.005), LLY: 70.56 (+0.03)
Shares of PODD Down 28.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 06, 4:39PM CST
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on December 15th, 2014 at $42.99. In approximately 2 months, Insulet has returned 28.19% as of today's recent price of $30.87.
PODD: 32.00 (-0.07)
Insulet Corporation to Report Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
Marketwired - Thu Feb 05, 4:20PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year 2014 on February 26, 2015 after the close of the financial markets.
PODD: 32.00 (-0.07)
Insulet Corporation to Present at the 2015 Leerink Global Healthcare Conference
Marketwired - Wed Feb 04, 3:01PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced that management will present at the 2015 Leerink Global Healthcare Conference in New York City on Wednesday, February 11, 2015 at 11:05 a.m. EST.
PODD: 32.00 (-0.07)
Insulet Extends Exclusive Agreement for Blood Glucose Monitoring
Marketwired - Tue Feb 03, 3:01PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced that it has extended its ongoing exclusive agreement with Abbott Laboratories (NYSE: ABT) to continue integration of the Abbott FreeStyle(R) blood glucose (BG) monitoring technology with Insulet's OmniPod System. The FreeStyle blood glucose meter is built into the OmniPod hand-held Personal Diabetes Manager (PDM), eliminating the need to carry and manage a separate meter or transfer BG results from device to device.
ABT: 46.09 (+0.87), PODD: 32.00 (-0.07)
Insulet Down 31.1% Since SmarTrend Downtrend Call (PODD)
Comtex SmarTrend(R) - Fri Jan 30, 10:58AM CST
SmarTrend identified a Downtrend for Insulet (NASDAQ ODD) on December 15th, 2014 at $42.99. In approximately 2 months, Insulet has returned 31.05% as of today's recent price of $29.64.
PODD: 32.00 (-0.07)
Insulet (PODD) Weak On High Volume Today
at The Street - Mon Jan 26, 9:03AM CST
Trade-Ideas LLC identified Insulet (PODD) as a weak on high relative volume candidate
PODD: 32.00 (-0.07)
Downgrade Alert for Insulet (PODD)
Comtex SmarTrend(R) - Mon Jan 26, 8:00AM CST
Insulet (NASDAQ ODD) was downgraded from Outperform to Market Perform at William Blair today. The stock closed yesterday at $32.22 on volume of 629,000 shares, below average daily volume of 859,000. Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes.
PODD: 32.00 (-0.07)
23.7% Return Seen to Date on SmarTrend Insulet Call (PODD)
Comtex SmarTrend(R) - Fri Jan 23, 9:36AM CST
SmarTrend identified a Downtrend for Insulet (NASDAQ ODD) on December 15th, 2014 at $42.99. In approximately 1 month, Insulet has returned 23.75% as of today's recent price of $32.78.
PODD: 32.00 (-0.07)
Today In SA PRO: Thursday, January 22
SA PRO Top Ideas - Seeking Alpha - Fri Jan 23, 4:00AM CST
Top Idea: Synergy Resources by Grizzly Bear: Short / Small-Cap / Oil & Gas Production / Other / Busted Growth / Industry Disruption / Buyside Author / 50-80% Downside Top Idea playing out : RWWI (Rand Worldwide) by Implied Value, December...
PODD: 32.00 (-0.07), SYRG: 11.87 (-0.12)
Wall Street Breakfast: ECB Poised To Launch Quantitative Easing
Wall Street Breakfast - at Seeking Alpha - Thu Jan 22, 5:31AM CST
KMI: 41.97 (+0.21), BBRY: 10.09 (+0.23), XOM: 93.37 (+1.00), GOOG: 549.01 (+6.08), BSX: 14.98 (+0.24), JNJ: 99.62 (+1.18), T: 34.66 (+0.05), DLTR: 76.82 (+0.97), SPY: 209.78 (+0.86), EBAY: 56.47 (+1.73), S: 5.23 (+0.08), QCOM: 70.88 (+0.49), GOOGL: 551.16 (+5.15), DG: 68.82 (+1.23), TMUS: 31.75 (+0.16), BCS: 15.77 (+0.12), AXP: 78.08 (-2.40), FDO: 77.86 (+0.31), PODD: 32.00 (-0.07), QQQ: 106.91 (+0.91), VZ: 49.31 (-0.21), SNDK: 82.81 (+0.51)
Downtrend Call Working As Insulet Stock Falls 25.4% (PODD)
Comtex SmarTrend(R) - Fri Jan 16, 9:13AM CST
SmarTrend identified a Downtrend for Insulet (NASDAQ ODD) on December 15th, 2014 at $42.99. In approximately 1 month, Insulet has returned 25.38% as of today's recent price of $32.08.
PODD: 32.00 (-0.07)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CRME: 9.76 (-0.14), SMSI: 1.60 (+0.07), DNBF: 22.59 (-0.41), PODD: 32.00 (-0.07), FLML: 14.15 (+0.15), QADB: 17.59 (+0.05), QADA: 20.36 (+0.14), WBKC: 23.75 (+0.03), COM.TO: 12.06 (-0.12), CMSB: 13.19 (+0.13), DWCH: 6.26 (-0.18)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CENX: 23.10 (-0.17), VBFC: 17.00 (-0.81), PODD: 32.00 (-0.07), FLML: 14.15 (+0.15), AXDX: 22.86 (-0.33), LPCN: 5.91 (+0.40), PEIX: 9.82 (+0.15), MTEX: 23.89 (+0.69), DWCH: 6.26 (-0.18)
Look for Shares of Insulet to Potentially Rebound after Yesterday's 17.25% Sell Off
Comtex SmarTrend(R) - Thu Jan 15, 4:06PM CST
Insulet (NASDAQ ODD) traded in a range yesterday that spanned from a low of $27.02 to a high of $33.30. Yesterday, the shares fell 17.2%, which took the trading range below the 3-day low of $38.42 on volume of 7.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PODD: 32.00 (-0.07)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Insulet Appoints John Fallon, M.D. as New Lead Director
Marketwired - Tue Feb 10, 4:00PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced that Dr. John Fallon has been appointed Lead Director of Insulet's Board of Directors. Dr. Fallon has served on the Insulet Board since 2012 and replaces Daniel Levangie who is resigning from the Insulet Board in order to assume the newly-created role of President, Insulet Drug Delivery.
PODD: 32.00 (-0.07)
Insulet Further Enhances Executive Leadership Team to Drive Improved Commercial and Operational Performance
Marketwired - Tue Feb 10, 4:00PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the appointment of Daniel Levangie to the newly-created role of President, Insulet Drug Delivery, and Ms. Shacey Petrovic to the position of Chief Commercial Officer, both reporting directly to Patrick Sullivan, President and Chief Executive Officer. As President, Insulet Drug Delivery, Mr. Levangie will focus on developing new growth opportunities for use of the OmniPod technology in the administration of a range of pharmaceutical products. In her role as Chief Commercial Officer, Ms. Petrovic will oversee all of the Company's commercial operations, including sales, marketing, managed care and business development. These appointments further strengthen the Company's senior leadership capabilities.
PODD: 32.00 (-0.07)
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 32.00 (-0.07), DXCM: 62.68 (+0.74), NVO: 43.76 (+0.61), MOM.VN: 0.210 (+0.005), LLY: 70.56 (+0.03)
Shares of PODD Down 28.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 06, 4:39PM CST
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on December 15th, 2014 at $42.99. In approximately 2 months, Insulet has returned 28.19% as of today's recent price of $30.87. PODD: 32.00 (-0.07)
Insulet Corporation to Report Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
Marketwired - Thu Feb 05, 4:20PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year 2014 on February 26, 2015 after the close of the financial markets.
PODD: 32.00 (-0.07)
Insulet Corporation to Present at the 2015 Leerink Global Healthcare Conference
Marketwired - Wed Feb 04, 3:01PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced that management will present at the 2015 Leerink Global Healthcare Conference in New York City on Wednesday, February 11, 2015 at 11:05 a.m. EST.
PODD: 32.00 (-0.07)
Insulet Extends Exclusive Agreement for Blood Glucose Monitoring
Marketwired - Tue Feb 03, 3:01PM CST
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced that it has extended its ongoing exclusive agreement with Abbott Laboratories (NYSE: ABT) to continue integration of the Abbott FreeStyle(R) blood glucose (BG) monitoring technology with Insulet's OmniPod System. The FreeStyle blood glucose meter is built into the OmniPod hand-held Personal Diabetes Manager (PDM), eliminating the need to carry and manage a separate meter or transfer BG results from device to device.
ABT: 46.09 (+0.87), PODD: 32.00 (-0.07)
Insulet Down 31.1% Since SmarTrend Downtrend Call (PODD)
Comtex SmarTrend(R) - Fri Jan 30, 10:58AM CST
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on December 15th, 2014 at $42.99. In approximately 2 months, Insulet has returned 31.05% as of today's recent price of $29.64. PODD: 32.00 (-0.07)
Insulet (PODD) Weak On High Volume Today
at The Street - Mon Jan 26, 9:03AM CST
Trade-Ideas LLC identified Insulet (PODD) as a weak on high relative volume candidate
PODD: 32.00 (-0.07)
Downgrade Alert for Insulet (PODD)
Comtex SmarTrend(R) - Mon Jan 26, 8:00AM CST
Insulet (NASDAQ
ODD) was downgraded from Outperform to Market Perform at William Blair today. The stock closed yesterday at $32.22 on volume of 629,000 shares, below average daily volume of 859,000. Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes. PODD: 32.00 (-0.07)
23.7% Return Seen to Date on SmarTrend Insulet Call (PODD)
Comtex SmarTrend(R) - Fri Jan 23, 9:36AM CST
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on December 15th, 2014 at $42.99. In approximately 1 month, Insulet has returned 23.75% as of today's recent price of $32.78. PODD: 32.00 (-0.07)
Today In SA PRO: Thursday, January 22
SA PRO Top Ideas - Seeking Alpha - Fri Jan 23, 4:00AM CST
Top Idea: Synergy Resources by Grizzly Bear: Short / Small-Cap / Oil & Gas Production / Other / Busted Growth / Industry Disruption / Buyside Author / 50-80% Downside Top Idea playing out : RWWI (Rand Worldwide) by Implied Value, December...
PODD: 32.00 (-0.07), SYRG: 11.87 (-0.12)
Wall Street Breakfast: ECB Poised To Launch Quantitative Easing
Wall Street Breakfast - at Seeking Alpha - Thu Jan 22, 5:31AM CST
KMI: 41.97 (+0.21), BBRY: 10.09 (+0.23), XOM: 93.37 (+1.00), GOOG: 549.01 (+6.08), BSX: 14.98 (+0.24), JNJ: 99.62 (+1.18), T: 34.66 (+0.05), DLTR: 76.82 (+0.97), SPY: 209.78 (+0.86), EBAY: 56.47 (+1.73), S: 5.23 (+0.08), QCOM: 70.88 (+0.49), GOOGL: 551.16 (+5.15), DG: 68.82 (+1.23), TMUS: 31.75 (+0.16), BCS: 15.77 (+0.12), AXP: 78.08 (-2.40), FDO: 77.86 (+0.31), PODD: 32.00 (-0.07), QQQ: 106.91 (+0.91), VZ: 49.31 (-0.21), SNDK: 82.81 (+0.51)
Downtrend Call Working As Insulet Stock Falls 25.4% (PODD)
Comtex SmarTrend(R) - Fri Jan 16, 9:13AM CST
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on December 15th, 2014 at $42.99. In approximately 1 month, Insulet has returned 25.38% as of today's recent price of $32.08. PODD: 32.00 (-0.07)
Nasdaq stocks posting largest volume increases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CRME: 9.76 (-0.14), SMSI: 1.60 (+0.07), DNBF: 22.59 (-0.41), PODD: 32.00 (-0.07), FLML: 14.15 (+0.15), QADB: 17.59 (+0.05), QADA: 20.36 (+0.14), WBKC: 23.75 (+0.03), COM.TO: 12.06 (-0.12), CMSB: 13.19 (+0.13), DWCH: 6.26 (-0.18)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jan 15, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CENX: 23.10 (-0.17), VBFC: 17.00 (-0.81), PODD: 32.00 (-0.07), FLML: 14.15 (+0.15), AXDX: 22.86 (-0.33), LPCN: 5.91 (+0.40), PEIX: 9.82 (+0.15), MTEX: 23.89 (+0.69), DWCH: 6.26 (-0.18)
Look for Shares of Insulet to Potentially Rebound after Yesterday's 17.25% Sell Off
Comtex SmarTrend(R) - Thu Jan 15, 4:06PM CST
Insulet (NASDAQ
ODD) traded in a range yesterday that spanned from a low of $27.02 to a high of $33.30. Yesterday, the shares fell 17.2%, which took the trading range below the 3-day low of $38.42 on volume of 7.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PODD: 32.00 (-0.07)
